Abstract:INTRODUCTION:Vesicular monoamine transporters 2 (VMAT2) in the brain serve as transporter for packaging monoamine in vesicles for normal CNS neurotransmission. Several VMAT2 imaging agents, [11C]-(+)-DTBZ, dihydrotetrabenazine and [18F]FP-(+)-DTBZ (9-O-fluoropropyl-(+)-dihydro tetrabenazine, a.k.a. [18F]AV-133), are useful for studying the changes in brain function related to monoamine transmission by in vivo imaging. Deuterated analogs have been reported targeting VMAT2 binding sites.METHODS:A novel deuterated [18F]9-O-hexaduterofluoropropyl-(+)-dihydrotetrabenazine, [18F]D6-FP-(+)-DTBZ, [18F]1, was prepared as a VMAT2 imaging agent. This 18F agent which targeted VMAT2 was evaluated by in vitro binding, in vivo biodistribution and microPET imaging studies in rodents.RESULTS:The one step radiolabeling reaction led to the desired [18F]D6-FP-(+)-DTBZ, [18F]1, which showed excellent binding affinity to VMAT2 (Ki=0.32±0.07nM) comparable to that of FP-(+)-DTBZ (Ki=0.33±0.02nM) using [18F]FP-(+)-DTBZ and rat striatum membrane homogenates. In vivo biodistribution in normal rats showed that 1, exhibited excellent brain uptake and comparable high ratio of striatum to cerebellum (target/background) ratio at 1h after injection (ratio of 6.05±0.43 vs 5.66±0.72 for [18F]FP-(+)-DTBZ vs [18F]1, respectively). MicroPET imaging studies in rats further confirm that the striatum with high VMAT2 concentration was clearly delineated in normal rat brain after iv injection of [18F]1. We observed minor changes of metabolism in rat plasma between these two agents; however, the changes showed little effect on regional brain uptake and retention.CONCLUSIONS:The results reported here lend support for using [18F]D6-FP-(+)-DTBZ, [18F]1, as in vivo PET imaging agent for VMAT2 binding in the brain.

VMAT structures reveal exciting targets for drug development

Neurotransmitter recognition by human vesicular monoamine transporter 2

Transport and inhibition mechanisms of human VMAT2

Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines

Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2

Engineering of a mammalian VMAT2 for cryo-EM analysis results in non-canonical protein folding

Drug inhibition and substrate alternating flipping mechanisms of human VMAT2

Structural mechanisms for VMAT2 inhibition by tetrabenazine

Structural snapshots of human VMAT2 reveal insights into substrate recognition and proton coupling mechanism

Tricyclic and tetracyclic antidepressants upregulate VMAT2 activity and rescue disease-causing VMAT2 variants

Vesicular neurotransmitter transporter trafficking in vivo

Effect of vesicular monoamine transporter-2 gene expression on the metabolites of dopamine in MN9D cells

Mapping the Target Localization and Biodistribution of Non-Radiolabeled VMAT2 Ligands in rat Brain

Structural Basis for Monoclonal Antibody Therapy for Transthyretin Amyloidosis

Recent Advances and Challenges of the Drugs Acting on Monoamine Transporters.

Synthesis and Structure-Activity Relationships for Glutamate Transporter Allosteric Modulators

9-Cyclopropylmethoxy-dihydrotetrabenazine and Its Stereoisomers As Vesicular Monoamine Transporter-2 Inhibitors

Structural insights into VAChT neurotransmitter recognition and inhibition

Hvmat2: A Target of Individualized Medication for Parkinson's Disease.

Deuterated 18F-9-o-hexadeutero-3-fluoropropoxyl-(+)-dihydrotetrabenazine (D6-FP-(+)-DTBZ): A Vesicular Monoamine Transporter 2 (VMAT2) Imaging Agent.